Business Context and Reporting Period
This Form 8-K Current Report was filed by Halozyme Therapeutics, Inc. on May 24, 2013, covering events occurring on May 20, 2013. The filing addresses a significant change in executive leadership within the Company's finance department.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on personnel changes and associated compensation adjustments.
Material Changes
- Resignation: Kurt A. Gustafson resigned as Vice President and Chief Financial Officer, effective May 20, 2013, to pursue other opportunities.
- Appointment: David A. Ramsay, previously Vice President of Corporate Development, was appointed as the new Vice President and Chief Financial Officer, effective May 20, 2013.
- Compensation Adjustment: Mr. Ramsay's annual salary was adjusted to $350,000 (prorated for the remainder of the year). He received stock options for 117,500 shares and restricted stock unit awards for 70,500 shares. He is also eligible for a target bonus of 40% of his base salary under the 2013 Senior Executive Incentive Plan.
Outlook, Risks, and Management Commentary
The filing notes that Mr. Ramsay brings over 20 years of corporate financial experience, including prior service as CFO at the Company (2003–2009) and at Lathian Systems and ICN Pharmaceuticals. There are no arrangements or understandings between Mr. Ramsay and other persons regarding his appointment. The Company issued a press release on May 23, 2013, to publicly announce these changes.
Investor Verification Checklist
- Verify the effective date of the CFO transition (May 20, 2013).
- Confirm the specific equity awards granted to the new CFO (117,500 options and 70,500 RSUs).
- Review the attached press release (Exhibit 99.1) for additional context on the leadership change.
- Note that no financial results or guidance are provided in this specific filing.